Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Beijing, China Clinical Trials

A listing of Beijing, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (48) clinical trials

Safety and Efficacy Evaluation of IM19 CAR-T Cells

Assessment of the Safety and Feasibility of Administering T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell leukemia or CD19+ B-ALL patients and determine the MTD,LTD and the best dosage.

Phase

0.0 miles

Learn More »

DCHA as Postremission Therapy for AML With t(8;21)

Treatment regimen HA homoharringtonine 2mg IV d1-5 cytarabine( Ara-C) 1500mg/m2(<60 year old) ; 1000mg/m2(>60 year old) IV q12h DCHA Decitabine 20mg/m2 d8-12 Chidamide 30mg twice/week P.O. for two weeks per cycle (four doses totally) cytarabine( Ara-C) 1500mg/m2(<60 year old) ; 1000mg/m2(>60 year old) IV q12h d1,3,5 homoharringtonine 2mg IV d10-14

Phase

0.0 miles

Learn More »

Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

The purpose of this study is to evaluate the safety and effectiveness of autologous gp96 treatment of gastric cancer.

Phase

0.0 miles

Learn More »

Combination of Chemotherapy SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs

In this study, participants with relapsed or refractory primary mediastinal large B-cell lymphoma (rrPMBCL) will receive GVD (Gemcitabine, Vinorelbine and Doxorubicine) chemotherapy and PD-1 antibodySHR-1210 with or without low-dose Decitabine priming. The safety and feasibility of combined regimens will be evaluated in phase I study. The subsequent phase II study ...

Phase

0.0 miles

Learn More »

SHR-1210 Alone or in Combination With Decitabine in Relapsed or Refractory Hodgkin Lymphoma

The purpose of this study is to evaluate whether treatment with the study drug decitabine in combination with SHR-1210 is safe and feasible, is more effective than treatment with SHR-1210 alone,and reverse the resistance of Anti-PD-1 antibody in patients with HL.

Phase

0.0 miles

Learn More »

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

PRIMARY OBJECTIVES: I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD19/CD22 vector (referred to as tanCART-19/22 cells). II. Determine duration of in vivo survival of tanCART-19/22 cells. RT-PCR (reverse transcription polymerase chain reaction) analysis of whole blood will be used to detect ...

Phase

0.0 miles

Learn More »

A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma

PRIMARY OBJECTIVES: To evaluate the feasibility and safety of UCART019 in patients with relapsed or refractory CD19+ leukemia and lymphoma. To evaluate the duration of in vivo persistence of adoptively transferred T cells, and the phenotype of persisting T cells. Real Time polymerase chain receptor (RT-PCR) analysis of peripheral blood(PB), ...

Phase

0.0 miles

Learn More »

Decitabine Followed by Donor Lymphocyte Infusion for Patients With Relapsed Acute Myeloblastic Leukemia(AML) After Allogeneic Stem Cell Transplantation

Decitabine can up-regulate a series of immune associated proteins, including cancer testis antigens (CTA), major histocompatibility complex (MHC), co-stimulatory molecules and adhesion molecules, which suggests a potential benefit for a following adoptive T cell therapy. In addition, decitabine induce FOXP3 expression in CD4+ T cells and convert CD4+ T cells ...

Phase

0.0 miles

Learn More »

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

PRIMARY OBJECTIVES: I. Determine the safety and feasibility of the chimeric antigen receptor T cells transduced with the anti-CD20 vector (referred to as CART-20 cells). II. Determine duration of in vivo survival of CART-20 cells. RT-PCR analysis of whole blood will be used to detect and quantify survival of CART-20 ...

Phase

0.0 miles

Learn More »

The Study to Evaluate JS001 in Patients With Advanced GC ESCC NPC HNSCC

Overall Design: This is a multicenter, open-label, phase Ib/II clinical study of recombinant humanized anti-programmed death receptor 1 (PD-1) monoclonal antibody for injection (JS001) in patients with gastric adenocarcinoma (GC), esophageal squamous cell carcinoma (ESCC), nasopharyngeal carcinoma (NPC), or head and neck squamous cell carcinoma (HNSCC). On the basis of ...

Phase

0.0 miles

Learn More »